1.Gallucci BB. Selected concepts of cancer as a disease: from the Greeks to 1900. Oncol Nurs Forum. 1985 Jul-Aug;12(4):67-71.

2.Kardinal C, Yarbro JA. Conceptual history of cancer. Semin Oncol 1979;6:396–408.

3.Erenpreisa J ,Cragg  S.M. (2007).Cancer: A matter of life cycle?cell Biology  International  31,1507-1510

4.Johnstone W.R  , Ruefli A.A ,lowe W. S.( 2002).Apoptosis : A link  between cancer genetics and chemotherapy. Cell 108, 153-164

5.Akulapalli Sudhakar, History of Cancer, Ancient and Modern Treatment Methods. J Cancer Sci Ther. 2009 Dec 1; 1(2): 1–4.

6.Kitada  S , Pedersen  I , Schimmer  A , Reed J. (2002).Dysregulation  of apoptosis genes in hematopoietic malignancies.Oncogene 21,3459-3474

7.Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004 May 27;429(6990):457-63.

8. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10(8): 789-99.
9. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, et al. Genetic alterations during colotectal- tumor development. N Engl J Med. 1988; 319(9): 525-532.
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70.
11. Sonnenschein C, Soto AM. Theories of carcinogenesis: an emerging perspective. Semi Cancer Biol. 2008; 18(5): 372-7.
12. Cross ML, Cook AM, Lin S, Chen JN, Rubinstein LA. Rapid Analysis of Angiogenesis

Drugs in a Live Fluorescent Zebrafish Assay. Arterioscler Thromb Vasc Biol. 2003; 23: 911-912.

13. Ruegg C. Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. Journal of Leukocyte Biology. 2006; 80(4): 627-684.
14. Pandya N, Dhalla N, Santani D. Angiogenesis—a new target for future therapy. Vascular Pharmacology. 2006; 44(5): 265–274.
15. Dudley A, Cloer E, Melero-Martin J. The Role of Bone Marrow-Derived Progenitor Cells in Tumor Growth and Angiogenesis. Stem Cells and Cancer Stem Cells, 2012; 8: 45-54.
16. Pasquet M, Golzio M, Mery E, Rafii A, et al. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. International Journal of Cancer. 2010; 126(9): 2090–2101.
17. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
18. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer 2012; 12:307-313.
19. Diamandopoulus GT. Cancer. An historical perspective. Anticancer Res. 1996;16:1595–1602.
20. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Jr, Gansler TS. Cancer Medicine. Decker Inc; 2003.
21. Encyclopedia Britannica. See entries on Medicine, History of Cancer.
22. Gallucci BB. Selected concepts of cancer as a disease. From the Greeks to 1900. Oncol Nurs Forum. 1985;12:67–71.

23.Diamandopoulus GT. Cancer. An historical perspective. Anticancer Res 1996;16:1595–1602.

24. Kufe, DW.; Pollock, RE.; Weichselbaum, RR.; Bast, RC., Jr; Gansler, TS. Cancer Medicine. Decker Inc; 2003.
25. Masahito Jimbo, MD, PhD, MPH, Donald E. Nease, Jr, MD, Information Technology and Cancer Prevention, CA Cancer J Clin 2006; 56:26-36
26. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10(8): 789-99.
27. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, et al. Genetic alterations during colotectal- tumor development. N Engl J Med. 1988; 319(9): 525-532.
28. Sonnenschein C, Soto AM. Theories of carcinogenesis: an emerging perspective. Semi Cancer Biol. 2008;  18(5): 372-7.
29. Narod SA, Foulkes WD. "BRCA1 and BRCA2: 1994 and beyond". Nature Reviews on Cancer. 2004; 4 (9): 665–676. 

30- Staal SP, Huebner k, Croce CM, Parsa N, et al. The akt-1 proto oncogene maps to human chromosome 14, band q32, a site of chromosome rearrangement in some hematopoietic neoplasma. Journal of Genomics. 1988; 2: 96-98.

31. Thomas RK, et al. High-throuphut oncogene mutation profiling in human cancer. Nature Genetics. 2007; 39: 347-351.
32. National RC. Committee to Assess Health Risks from Exposure to Low Levels of Inoizing Radiation: BEIR VII Phase 2. Washington. 2011.
33. Fazel R, Krumholz HM, Wang R, et al. Exposure to Low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009; 361(9): 849-57.
34. Seto M, Honma K, Nakagawa M. Diversity of genome profiles in malignant lymphoma. Cancer Science. 2010; 101: 573-578.
35. Pakin DM. The global health burden of infection-associated cancers in the years 2002. Int J Cancer.2006; 118(12) : 3030-44.

36.Berman JJ (March 2004). "Tumor classification: molecular analysis meets Aristotle". BMC Cancer. 4 (1): 10. PMC 415552 . PMID 15113444. doi:10.1186/1471-2407-4-10

37.Berman JJ (November 2004). "Tumor taxonomy for the developmental lineage classification of neoplasms". BMC Cancer. 4 (1): 88. PMC 535937 .

38.Lemoine, Nigel Kirkham, Nicholas R. (2001). Progress in pathology. London: Greenwich Medical Media. p. 52. ISBN 9781841100500.

39.Definition of Carcinoma". Retrieved 27 January 2014.

40.International Agency for Research on Cancer (2002). Pathology and Genetics of Tumours of Soft Tissue and Bone. St. Louis: WHO Press. ISBN 9789283224136.

41.Colvin G. A.; Elfenbein G. J. (2003). "The latest treatment advances for acute myelogenous leukemia". Medicine and Health, Rhode Island. 86 (8): 243–6.

42.Scarpa A, Moore PS, Rigaud G, Meenestrina F. Genetic in primary mediastinal B-cell lymphoma: an updata. Leukemia & Lymphoma. 2001; 411(2): 47-53.

43. Masahito Jimbo, MD, PhD, MPH, Donald E. Nease, Jr, MD, Information Technology and Cancer Prevention, CA Cancer J Clin 2006; 56:26-36
44. Jain K. Personalised medicine for cancer: from drug development into clinical practice. Expert Opinion on Pharmacotherapy. 2005;6(6):1463–1476.

45.Carneiro Teixeira JF, Maia-Lemos PDS, Cypriano MDS, Pellegrini Pisani L. Obesity in Survivors of Childhood Cancer: a Review. Pediatr Endocrinol Rev. 2017 Sep;15(1):33-39.

4.6Kim SY, Wie GA, Cho YA, Kang HH, Ryu KA, Yoo MK, Jun S, Kim SA, Ha K, Kim J, Cho YH, Shin S, Joung H. The Role of Red Meat and Flavonoid Consumption on Cancer Prevention: The Korean Cancer Screening Examination Cohort. Nutrients. 2017 Aug 25;9(9).

47.Liu SW, Cai Y, Zeng XY, Yin P, Qi JL, Liu YN, Liu JM, Zhao ZP, Zhang M, Wang LM, Wang LJ, Xue M, Zhou MG. Deaths and life expectancy losses attributable to diet high in sodium in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Aug 10;38(8):1022-1027.

48.Lim SG¹, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol. 2009 Aug;24(8):1352-7.

49.Nannini P¹, Sokal EM¹. Hepatitis B: changing epidemiology and interventions. Arch Dis Child. 2017 Jul;102(7):0

50.Siang Yong Tan, MD, JD¹ and Yvonne Tatsumura, MA, MD. George Papanicolaou (1883–1962): Discoverer of the Pap smear. Singapore Med J. 2015 Oct; 56(10): 586–587.

51. William WN Jr, Heymach JV, Kim ES, et al. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov. 2009; 8(3): 213-25.

52.Strom T, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, Fulp W, Thapa R, Coppola D, Kim S, Frakes J, Foekens J, Mulé JJ, Torres-Roca JF. Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer. 2017 Aug 29;84:304-314.

53.Lawrence TS, Ten Haken RK, Giaccia A. Principles of Radiation Oncology. In: DeVita VT Jr., Lawrence TS, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 8thed. Philadelphia: Lippincott Williams and Wilkins, 2008.

54.Tai-You Ha. The Role of Regulatory T Cells in Cancer. Immune Netw. 2009 Dec; 9(6): 209–235.

55.Per thor Straten and Federico Garrido. Targetless T cells in cancer immunotherapy. J Immunother Cancer. 2016; 4: 23.

56.Francesmary Modugno, Robin Laskey, Ashlee L Smith, Courtney L Andersen, Paul Haluska, and Steffi Oesterreich^3, Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer. Author manuscript; available in PMC 2013 Dec 1.

57.Endogenous Hormones and Breast Cancer Collaborative Group. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studiesBr J Cancer. 2011 Aug 23; 105(5): 709–722

58.Differentiation therapy of human cancer : basic science and clinical application. Pharmacology & therapeutics 90 ,105-156

59.Miller   W , Waxman  S. ( 2002). Differentiation induction as a treatment for  hematologic  malignancies. Oncogene 21 , 3496-3506

60.Leszczyniecka M ,Roberts T ,Dent P ,Grant S ,Fisher P.( 2001).Differentiation therapy of human cancer : basic science and clinical application. Pharmacology & therapeutics 90 ,105-156

61.Spira A.I , Carducci M.A.( 2003) . Differentiation therapy. Current opinion  in pharmacology 3, 338-343

62.Ashim K. Mitra, Vibhuti Agrahari, Abhirup Mandal, Kishore Cholkar, Chandramouli Natarajan, Sujay Shah, Mary Joseph, Hoang My Trinh, Ravi Vaishya, Xiaoyan Yang, Yi Hao, Varun Khurana, and Dhananjay Pal.NOVEL DELIVERY APPROACHES FOR CANCER THERAPEUTICS. J Control Release. 2015 Dec 10; 219: 248–268.

63.Catriona Elizabeth Mactier¹ and Md Serajul Islam^1,2Author information  Article notes  Copyright and License information . Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities. Oncol Rev. 2012 Oct 2; 6(2): e14.